Publications by authors named "Christopher Su"
Article Synopsis
- Time toxicity in cancer treatment means that too many doctor visits and treatments can hurt how patients feel and live their lives.
- The review looks at how this affects patients with non-Hodgkin lymphoma and multiple myeloma, especially when choosing treatments like chemo or specific drugs.
- It also discusses ways to reduce these burdens while still keeping the treatments effective and safe for patients.
Background: Patients with multiple myeloma (MM) may be on therapy for years, which can lead to financial toxicity (FinTox) or time toxicity (TimeTox). The prevalence, predictors, and quality of life (QOL) impacts of FinTox and TimeTox during different phases of MM treatment have not been characterized.
Patients And Methods: We conducted a single-center cross-sectional survey of patients with MM who had undergone transplantation.
Immunotherapy has transformed lung cancer management, but PSC remains an aggressive subtype with a poor prognosis. This study investigates the differential expression of PD-L1 and alternative immune checkpoints (ICs; B7x, B7-H3, and HHLA2), and genetic alterations in PSCs. Tumor specimens of 41 PSC patients were evaluated.
View Article and Find Full Text PDFDefining the Role of the Modern Oncology Provider in Mitigating Financial Toxicity.
J Am Coll Radiol
January 2023
Financial toxicity, the cumulative financial hardships resulting from cancer diagnosis and treatment, is a growing problem in the United States. With the proliferation of costly novel therapeutics and improved cancer survival, financial toxicity will remain a major issue in cancer care delivery. Frontline oncology providers serve as gatekeepers in the medical system and, as such, could play essential roles in recognizing and addressing financial toxicity.
View Article and Find Full Text PDFBackground: PARP (poly(ADP-ribose) polymerase) inhibitors (PARPi) are now standard of care in metastatic castrate-resistant prostate cancer (mCRPC) patients with select mutations in DNA damage repair (DDR) pathways, but patients with ATM- and BRCA2 mutations may respond differently to PARPi. We hypothesized that differences may also exist in response to taxanes, which may inform treatment sequencing decisions.
Methods: mCRPC patients (N = 158) with deleterious ATM or BRCA2 mutations who received taxanes, PARPi, or both were retrospectively identified from 11 US academic centers.
Ocular immune-related adverse events are a relatively rare complication of immune checkpoint inhibitors. Common ocular toxicities range from dry eyes to inflammatory uveitis and ocular myasthenia gravis. Here, we present the case of a 55-year-old woman with recurrent urothelial carcinoma of the ureter after initially being managed with neoadjuvant cisplatin-based chemotherapy and surgical resection.
View Article and Find Full Text PDFIntroduction: Important differences exist between the presentation, treatment, and survivorship of patients and survivors with blood cancers. Furthermore, existing research in financial toxicity has not fully addressed the relationship between medical care utilization and patient-reported outcomes of financial barriers and distress. We answered these questions by using a nationally representative survey.
View Article and Find Full Text PDFArticle Synopsis
- * Data from the COVID-19 and Cancer Consortium indicates that those treated for B-lymphoid malignancies within the past year have a greater severity of COVID-19 compared to those who were not recently treated.
- * The study highlights the need for tailored strategies to protect this vulnerable group of patients, as recent treatment appears to be a key factor in increased COVID-19 risk.
Article Synopsis
- The study aimed to explore how a new geriatric risk index, which considers factors like age and comorbidities, impacts COVID-19 severity and mortality among older adults with cancer.
- It analyzed a cohort of 5,671 patients aged 60 and older who were part of a global cancer registry during the pandemic, focusing on outcomes based on the developed risk index.
- Results showed that nearly 20% of patients were labeled as high risk, and these individuals faced significantly worse COVID-19 severity compared to those classified as standard risk, with a mortality rate of 16.2% among all participants.
Article Synopsis
- - This study analyzes the efficacy of enfortumab vedotin (EV) for treating advanced urothelial cancer (aUC) in patients not previously well represented in clinical trials, focusing on real-world experiences from a retrospective study called UNITE.
- - The results from 304 patients indicated a 52% overall response rate to EV monotherapy, with similar responses in various patient subsets, including those with significant comorbidities that were often excluded from clinical trials.
- - Overall survival was about 14.4 months, showing that EV can be effective even for patients with variant histology or specific genetic alterations, aligning with earlier clinical trial findings.
Unlabelled: Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib) are US Food and Drug Administration-approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring / mutations, but the relative efficacy of PARP inhibition in - versus -altered mCRPC is understudied.
Methods: We conducted a multicenter retrospective analysis involving 12 sites. We collected genomic and clinical data from 123 patients with /-altered mCRPC who were treated with PARP inhibitors.
Background: Enfortumab vedotin (EV) is approved to treat metastatic urothelial carcinoma (mUC) following platinum and PD1/L1 inhibitors. Since the outcomes and patterns of therapy of patients following discontinuation of EV are unknown, we conducted a retrospective study to assess this issue.
Methods: Data were retrospectively obtained from patients with mUC following discontinuation of EV after prior platinum-based chemotherapy and PD1/L1 inhibitors.
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
J Hematol Oncol
July 2021
The pace of innovation of multiple myeloma therapy in recent years is remarkable with the advent of monoclonal antibodies and the approval of novel agents with new mechanisms of action. Emerging therapies are on the horizon for clinical approval with significant implications in extending patient survival and advancing closer to the goal of a cure, especially in areas of immunotherapy such as chimeric antigen receptor T cells, bispecific T cell engager antibodies, antibody drug conjugates, newer generations of monoclonal antibodies, and small molecule inhibitor and modulators. This review provides an update of current myeloma therapeutics in active preclinical and early clinical development and discusses the mechanism of action of several classes of novel therapeutics.
View Article and Find Full Text PDFPurpose: Since Affordable Care Act (ACA) implementation in 2014, studies have demonstrated gains in insurance coverage for cancer survivors < 65 years. We assessed the impact of ACA implementation on financial barriers to care by stratifying survivors at age 65 years, when individuals typically become Medicare-eligible.
Methods: We used data from respondents with cancer in the 2009-2018 National Health Interview Survey.
Article Synopsis
- A study investigated the impact of convalescent plasma treatment on 30-day mortality rates among hospitalized patients with hematologic cancers and COVID-19, as this group is known to have poor outcomes.
- The research utilized a retrospective cohort design, analyzing data from the COVID-19 and Cancer Consortium registry, focusing on patients admitted between March 2020 and January 2021.
- Results indicated that convalescent plasma treatment significantly improved 30-day mortality (HR, 0.60), with the benefit persisting even after accounting for potential confounding factors (HR, 0.52).
Article Synopsis
- A systematic scoping review examined interventions aimed at reducing medical financial hardship, specifically focusing on out-of-pocket healthcare expenses, analyzing studies published from 1980 to 2020.
- Out of 2,412 articles screened, only 12 met the criteria for inclusion, revealing that while behavioral and some psychosocial outcomes improved, no significant reduction in out-of-pocket expenses or improvements in health status were reported.
- The review highlights a lack of rigorous studies in this area, suggesting that future research should establish clearer intervention definitions, standardized outcome measurements, and robust study designs to better understand and mitigate financial hardship in healthcare.
Objectives: To evaluate outcomes of patients achieving a post-treatment pathological stage of
Patients And Methods: Patients from 10 international centres who underwent NAC for cT2-4aN0-1 MIBC and achieved
Purpose: Several immune checkpoint inhibitors (ICIs) are FDA approved for treatment of genitourinary (GU) malignancies. We aim to determine demographic and clinicopathologic characteristics that significantly affect clinical outcomes in patients with advanced stage GU malignancies treated with ICIs.
Materials And Methods: We performed a single-center, consecutive, retrospective cohort analysis on patients with metastatic or unresectable GU malignancies who were treated with ICIs at the University of Michigan.
Background: Appropriate therapy for carbapenem-resistant (CRKP) bloodstream infection (BSI) is often given late in the course of infection, and strategies for identifying CRKP BSI earlier are needed.
Methods: A retrospective case-control study was performed at a tertiary care hospital, university hospital, and community hospital in Bronx, New York. All participants had a blood culture sent and received an antibiotic within 48 hours of the culture.
Importance: Several immune checkpoint inhibitors (ICIs) are approved for use in patients with metastatic renal cell carcinoma (mRCC), but the efficacy and safety of ICI rechallenge in mRCC is unknown.
Objective: To evaluate the safety and efficacy of ICI rechallenge in patients with mRCC.
Design, Setting, And Participants: This multicenter, retrospective cohort study included consecutive patients with mRCC from 9 institutions in the US who received at least 2 separate lines of ICI (ICI-1, ICI-2) between January 2012 and December 2019.